Liukaityte R, Stenberg VY, Kleinauskas A, Juzenas P, Urbanucci A, Juzeniene A (2025)
Combination of PSMA targeting alpha-emitting radioligand [²¹²Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models
Med Oncol, 42 (8), 362
DOI 10.1007/s12032-025-02925-9, PubMed 40694184

Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Menezes R, Gregoricchio S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden MS, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A et al. (2025)
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Cell Rep Med, 6 (7), 102215
DOI 10.1016/j.xcrm.2025.102215, PubMed 40609538

Bouska A, Zhang W, Sharma S, Holte H, Shah RA, Lone WG, Soma MA, Yang R, Liu X, Mehmood S, Chawla RS, Cappelli LV, Fiore D, Gong Q, Heavican-Foral TB, Cannatella JJ, Amador C, Arif A, Smith LM, Lim ST, Ong CK, Feldman AL, Du MQ, Perry AM, de Leval L et al. (2025)
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
Am J Hematol (in press)
DOI 10.1002/ajh.27736, PubMed 40510016